Novel mechanisms of resistance to EGFR inhibitory drugs in non-small cell lung cancer
EGFR activating mutations are present in 10-40% of non-small cell lung cancer. Such mutations render tumour cells sensitive to EGFR tyrosine kinase inhibitors (EGFR TKIs), with responses of up to 80% in populations selected for the presence of an activating mutation. Unfortunately, almost all patien...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2012
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.568316 |